Valeant Pharma to Buy Sanitas - Analyst Blog
May 25 2011 - 7:45AM
Zacks
In an effort to expand its European branded generics business,
Valeant Pharmaceuticals International Inc. (VRX)
recently announced that it has entered into an agreement to acquire
Kaunas, Lithuania-based specialty pharmaceuticals company AB
Sanitas for approximately EUR314 million in cash.
87.2% of the outstanding shares of Sanitas have already been
agreed to be sold to Valeant Pharma. Following acquisition of the
controlling interest, Valeant Pharma will proceed to make a
mandatory tender offer to acquire the remaining minority interest.
The company will also take over approximately EUR50 million of
Sanitas’ debt. The acquisition of the controlling interest is
expected to close in the third quarter of this year and the
mandatory tender offer is expected to close in the fourth
quarter.
Sanitas has a broad branded generics portfolio, which is
marketed across Central and Eastern Europe, primarily Poland,
Russia and Lithuania. Sanitas’ 390 products, primarily dermatology,
ophthalmology and hospital injectables, will boost Valeant Pharma’s
European branded generic portfolio. Approximately 80% of Sanitas’
products are non-reimbursable and not exposed to pricing pressures
imposed by governments.
The Sanitas deal comes on the heels of Valeant Pharma’s failed
offer to acquire Cephalon Inc. (CEPH). Valeant
Pharma had expressed an interest in acquiring Cephalon for $5.7
billion. However, Cephalon rejected the offer and subsequently
entered into a definitive agreement to be acquired by Teva
Pharmaceutical Industries Ltd. (TEVA).
Valeant Pharma is expanding its global presence through
accretive acquisitions. Valeant Pharma in its current form in fact
emerged from the merger of Biovail and Valeant in September
2010.
Our Recommendation
We have a Neutral recommendation on Valeant Pharmaceuticals. Our
long-term stance is supported by the Zacks #3 Rank (Hold rating)
carried by the company in the short run.
Overall, we believe the combined Biovail/Valeant entity is a
unique company as it offers global reach, a diversified revenue
base, a favorable tax structure and limited patent exposure.
Moreover, accretive acquisitions add to the company’s investment
thesis. However, the company’s failure to clinch the Cephalon
acquisition disappointed us. We therefore prefer to remain on the
sidelines.
CEPHALON INC (CEPH): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
Zacks Investment Research
Cephalon (NASDAQ:CEPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cephalon (NASDAQ:CEPH)
Historical Stock Chart
From Jul 2023 to Jul 2024